Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
25/06/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
17/06/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer | NASDAQ:AZN | AstraZeneca PLC |
16/06/2024 | 13:00 | Business Wire | CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
12/06/2024 | 23:35 | Business Wire | FARXIGA approved in the US for the treatment of pediatric type-2 diabetes | NASDAQ:AZN | AstraZeneca PLC |
12/06/2024 | 16:14 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
10/06/2024 | 13:00 | Business Wire | TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer | NASDAQ:AZN | AstraZeneca PLC |
06/06/2024 | 13:00 | PR Newswire (US) | I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer | NASDAQ:AZN | AstraZeneca PLC |
04/06/2024 | 16:02 | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities | NASDAQ:AZN | AstraZeneca PLC |
04/06/2024 | 15:10 | IH Market News | Economic Worries May Lead To Weakness On Wall Street | NASDAQ:AZN | AstraZeneca PLC |
04/06/2024 | 13:00 | PR Newswire (US) | AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024 | NASDAQ:AZN | AstraZeneca PLC |
02/06/2024 | 20:32 | Business Wire | TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
02/06/2024 | 14:05 | Business Wire | IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo | NASDAQ:AZN | AstraZeneca PLC |
02/06/2024 | 14:00 | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy | NASDAQ:AZN | AstraZeneca PLC |
28/05/2024 | 22:30 | GlobeNewswire Inc. | Cellectis Reports Financial Results for First Quarter 2024 | NASDAQ:AZN | AstraZeneca PLC |
28/05/2024 | 15:06 | Business Wire | ダトポタマブ デルクステカン、 進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、 化学療法と比較して臨床的に有意な全生存期間の改善を示す | NASDAQ:AZN | AstraZeneca PLC |
27/05/2024 | 22:55 | Business Wire | Datopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem Lungenkrebs | NASDAQ:AZN | AstraZeneca PLC |
27/05/2024 | 19:14 | Business Wire | Le datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameux | NASDAQ:AZN | AstraZeneca PLC |
27/05/2024 | 13:00 | Business Wire | Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
23/05/2024 | 19:52 | Business Wire | AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) | NASDAQ:AZN | AstraZeneca PLC |
22/05/2024 | 13:00 | Business Wire | AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 | NASDAQ:AZN | AstraZeneca PLC |
22/05/2024 | 00:44 | Business Wire | アストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定 | NASDAQ:AZN | AstraZeneca PLC |
21/05/2024 | 17:37 | Business Wire | AstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 an | NASDAQ:AZN | AstraZeneca PLC |
21/05/2024 | 17:36 | Business Wire | AstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030 | NASDAQ:AZN | AstraZeneca PLC |
21/05/2024 | 13:18 | IH Market News | CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News | NASDAQ:AZN | AstraZeneca PLC |
21/05/2024 | 08:00 | Business Wire | AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030 | NASDAQ:AZN | AstraZeneca PLC |
19/05/2024 | 23:17 | Business Wire | New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease | NASDAQ:AZN | AstraZeneca PLC |
13/05/2024 | 13:16 | IH Market News | Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More | NASDAQ:AZN | AstraZeneca PLC |
06/05/2024 | 08:00 | GlobeNewswire Inc. | Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca | NASDAQ:AZN | AstraZeneca PLC |
02/05/2024 | 13:00 | Business Wire | CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
01/05/2024 | 13:05 | Business Wire | AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio | NASDAQ:AZN | AstraZeneca PLC |